{"product_id":"abt-bcg-matrix","title":"(ABT) Abbott Laboratories BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Abbott Laboratories BCG Matrix helps you see how the company’s products or business units may fall into the classic Stars, Cash Cows, Question Marks, and Dogs categories for strategy and portfolio planning. The page already shows a real preview of the analysis, so you can review the actual format and content before purchasing. Buy the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFreeStyle Libre CGM, \u0026gt;$6B sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFreeStyle Libre is Abbott Laboratories’ clearest Star: Diabetes Care sales topped $6 billion in 2025, up from about $5.3 billion in 2024, and Libre remains the global CGM leader. The installed base kept rising across both insulin and non-insulin users, which widened Abbott Laboratories’ recurring revenue pool. It still needs launch spend and reimbursement wins, but the scale is already very large.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLibre 3 Plus and Libre Rio, 2025 expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLibre 3 Plus and Libre Rio extend Abbott Laboratories' Libre franchise into broader type 2 diabetes and connected monitoring, where adoption is still growing faster than the core CGM base. Abbott said the Libre platform has more than 6 million users, so these launches help defend share and lift device attachment. That keeps Libre in Star territory, not a mature cash cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMitraClip and TriClip structural heart repair\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbbott's MitraClip and TriClip keep it a major transcatheter repair player, with 2 edge-to-edge repair platforms. Structural heart care is still moving from open surgery to catheter-based treatment, so procedure volumes can keep rising. The category has high clinical value and repeat use, but Abbott still needs more physician training and trial data to widen adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAVEIR leadless pacing platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAVEIR leadless pacing is a growth Star for Abbott Laboratories. Abbott’s AVEIR DR dual-chamber system was FDA-approved in 2023, and leadless pacing is still early in adoption versus the much larger global pacemaker base, so installed scale is still building while the market expands.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA-cleared dual-chamber leadless pacing\u003c\/li\u003e\n\u003cli\u003eEarly installed base, high growth runway\u003c\/li\u003e\n\u003cli\u003eHigher launch costs now, but strong upside\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCardioMEMS heart-failure monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCardioMEMS sits in Abbott Laboratories’ Stars quadrant because heart-failure monitoring is a growing chronic-care niche: about 6.7 million Americans live with heart failure, yet use of implantable hemodynamic monitoring remains low. Abbott’s sensor creates recurring clinical touchpoints after implant, and the FDA-approved system for NYHA class II-III patients gives it a clear edge. Growth can still outpace the wider device market if Abbott keeps pushing physician education and payer coverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge, underused HF pool\u003c\/li\u003e\n\u003cli\u003eImplant drives repeat care\u003c\/li\u003e\n\u003cli\u003eReimbursement remains key\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAbbott’s Star Growth Engines: Libre, AVEIR, and CardioMEMS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAbbott Laboratories’ Stars are led by FreeStyle Libre, with 2025 Diabetes Care sales above $6 billion and more than 6 million users, so growth still outpaces maturity. AVEIR, MitraClip\/TriClip, and CardioMEMS also fit Star status because each serves an expanding market with rising adoption and clear clinical demand. These units need continued launch spend, but they still have strong runway.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eFreeStyle Libre\u003c\/td\u003e\n\u003ctd\u003eSales \u0026gt;$6B; 6M+ users\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAbbott Labs BCG Matrix shows which products to invest in, hold, or divest across Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuickly spot Abbott’s BCG quadrants to simplify portfolio decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eShows the source trail behind Abbott Laboratories assumptions, making the analysis easier to trust, verify, and use in decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnsure adult nutrition, mature global brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEnsure is Abbott Laboratories’ mature adult nutrition brand, sold through broad retail, pharmacy, and online channels. Adult nutrition is a low-growth, high-repeat category, so Ensure keeps producing steady cash with less launch spend than newer brands. That makes it a classic Cash Cow in Abbott Laboratories’ BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePediaSure pediatric nutrition, mature franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePediaSure is a mature pediatric nutrition franchise inside Abbott Laboratories’ Nutrition segment, which generated about $8.4 billion in 2024 sales. Demand is steady in mature markets, so the brand fits the Cash Cow profile: slow growth, reliable repeat use, and low marketing support versus its scale. Abbott Laboratories can keep the line efficient and turn that scale into dependable cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSimilac infant nutrition, large installed brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSimilac is a core Abbott infant nutrition brand, and Abbott’s Nutrition sales were about $8.5 billion in 2024. Infant formula is mature and tightly regulated, so growth is usually low single digits, but Similac’s scale and shelf space help protect margins. With stable supply, it acts like a Cash Cow: steady cash flow, limited new-capex need.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCore laboratory diagnostics, immunoassay and clinical chemistry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAbbott Laboratories' core lab diagnostics, immunoassay and clinical chemistry businesses serve hospitals and reference labs at scale, with installed systems driving recurring reagent sales and sticky cash flow.\u003c\/p\u003e\n\u003cp\u003eThese are mature markets, so growth spend is lower than in newer devices, while the segment keeps benefiting from high-volume test demand and an annuity-like revenue base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh installed base\u003c\/li\u003e\n\u003cli\u003eRecurring reagent demand\u003c\/li\u003e\n\u003cli\u003eStable, mature end markets\u003c\/li\u003e\n\u003cli\u003eLower growth capex need\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEstablished Pharmaceuticals, international generics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAbbott Laboratories' Established Pharmaceuticals is a Cash Cow: FY2025 sales were about $2.2 billion, built on mature branded generics and legacy therapies. These products sit in lower-growth niches, but they still throw off steady margin and cash across many countries. That cash helps fund Abbott Laboratories' R\u0026amp;D and newer growth bets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2025: steady $2.2B-scale revenue\u003c\/li\u003e\n\u003cli\u003eLow growth, high cash generation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAbbott’s Cash Cows: Steady, Sticky, and Cash-Generating\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAbbott Laboratories’ Cash Cows are mature, scale-led lines that throw off steady cash: Ensure, PediaSure, Similac, core diagnostics, and Established Pharmaceuticals. Abbott Laboratories’ Nutrition sales were about $8.5 billion in 2024, and Established Pharmaceuticals reached about $2.2 billion in FY2025. Low growth, repeat demand, and sticky channels keep capex and launch spend light.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash cow\u003c\/th\u003e\n\u003cth\u003eLatest scale\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eEstablished Pharma\u003c\/td\u003e\n\u003ctd\u003eFY2025: $2.2B\u003c\/td\u003e\n\u003ctd\u003eSteady cash\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAbbott Laboratories Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis Abbott Laboratories BCG Matrix preview is the exact document you’ll receive after purchase. No placeholders, no demo pages—just the full, professionally formatted file. What you see here is what you’ll download instantly. It’s ready to use for analysis, planning, or presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCOVID-19 diagnostics franchise, post-pandemic decline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbbott's COVID-19 diagnostics franchise is a Dog: demand is far below the 2020-2022 peak, so volumes and pricing have reset to a low base. In 2025, the line is still alive but contributes only a small, shrinking slice of Diagnostics sales as competition stays intense and growth remains weak.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBinaxNOW COVID-19 Ag, seasonal residual demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBinaxNOW COVID-19 Ag was a pandemic winner, but Abbott’s COVID-19 testing sales have fallen to a small, seasonal residual stream, far below the pandemic peak. Demand now spikes around respiratory-season waves and outbreaks, so it is episodic, not structural. That makes BinaxNOW a low-growth \"Dog\" that does not justify heavy expansion spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eID NOW SARS-CoV-2, low-run-rate molecular testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eID NOW SARS-CoV-2 has shifted from pandemic-scale use to a niche, install-driven test line, so volume upside is now limited and margins are weaker than Abbott's core diagnostics. Abbott reported 2025 sales of about $43.0 billion, but this COVID molecular line is no longer a growth driver inside that base. That profile fits the Dog box: low growth, low strategic pull, and keep-it-available economics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eStrip-based glucose meters, CGM displacement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrip-based glucose meters sit in Dogs: fingerstick testing keeps losing share to CGM, and Abbott's own FreeStyle Libre makes the legacy strip business less important over time. The category has low growth, weak pricing power, and little strategic upside, so it ties up cash better used in Abbott's newer diabetes devices. In Abbott's latest filings, Libre remains the main diabetes growth driver, while older strip systems look like a shrinking, cash-generating holdover.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFingerstick demand keeps falling.\u003c\/li\u003e\n\u003cli\u003eLibre weakens long-term strip demand.\u003c\/li\u003e\n\u003cli\u003eGrowth is slow and share is pressured.\u003c\/li\u003e\n\u003cli\u003eLegacy strips are cash traps.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLegacy low-volume generic Rx brands, saturated markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAbbott Laboratories’ legacy low-volume generic Rx brands sit in crowded, low-growth niches, so they can keep cash flowing but rarely drive new growth. When share is small and prices are commoditized, strategic value stays low, which fits Dog status in a BCG screen. These brands are better candidates for harvesting or pruning than for fresh investment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth, low share\u003c\/li\u003e\n\u003cli\u003eCash flow, not expansion\u003c\/li\u003e\n\u003cli\u003ePriced like a commodity\u003c\/li\u003e\n\u003cli\u003eBest for harvest or exit\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAbbott’s Dogs: Fading COVID Tests and Legacy Glucose Strips\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAbbott Laboratories’ Dogs are its fading COVID-19 tests and legacy strip-based glucose meters: both have low growth, weak pricing power, and little strategic lift. In 2025, Abbott sales were about $43.0 billion, but these lines were only a small, shrinking part of the mix. Best use is cash harvest, not new capital.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003cth\u003eBCG fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOVID tests\u003c\/td\u003e\n\u003ctd\u003eResidual, seasonal demand\u003c\/td\u003e\n\u003ctd\u003eLow growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFingerstick strips\u003c\/td\u003e\n\u003ctd\u003eShare loss to Libre\u003c\/td\u003e\n\u003ctd\u003eLow share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLingo consumer biosensor, early-stage wearables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbbott’s Lingo consumer biosensor targets the fast-growing metabolic wellness market, but the brand is still early and share is small. In 2024, Abbott said Lingo launched in the U.S. as a direct-to-consumer glucose biosensor.\u003c\/p\u003e\n\u003cp\u003eThat makes it a Question Mark: the category is attractive, but adoption versus Apple Watch, Oura, and other wearables is still unproven. Abbott is spending to build awareness before Lingo can scale into a Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLibre Rio, non-insulin type 2 CGM expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLibre Rio is a Question Mark for Abbott Laboratories because it opens a very large new pool: the IDF estimates 537 million adults live with diabetes, and about 90% have type 2. Abbott has the FreeStyle Libre platform and scale, but reimbursement and routine use in non-insulin type 2 are still early, so share is still being set. If adoption speeds up, this can turn into a major growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVolt PFA system, atrial fibrillation ablation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbbott’s Volt PFA system for atrial fibrillation sits in a fast-growing pulsed-field ablation market, where adoption is still early and share is not yet locked in. Abbott reported $11.9 billion in 2025 Medical Devices revenue, but Volt is still building its installed base against larger rivals like Medtronic and Boston Scientific. That makes it a classic Question Mark: high growth, low share, and heavy scale-up needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTricuspid therapy expansion, early structural-heart share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTricuspid repair and replacement are still early, and only 2 U.S. transcatheter options have clear clinical traction today: Abbott Laboratories TriClip and Edwards Lifesciences EVOQUE. That makes Abbott Laboratories a high-upside Question Mark, because share can scale fast if repair becomes standard, but the category can also stay niche. The prize is real, but the market is still forming.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 approved U.S. options\u003c\/li\u003e\n\u003cli\u003eEarly, still forming market\u003c\/li\u003e\n\u003cli\u003eHigh upside, high uncertainty\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNext-gen digital diagnostics and remote monitoring, early monetization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAbbott’s remote monitoring and connected-care tools are still in early monetization, so they fit Question Marks. They can grow fast, but share and revenue quality are not yet at Libre or core lab levels; if adoption improves, these units could shift into Stars. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly scale\u003c\/li\u003e\n\u003cli\u003eRevenue not proven\u003c\/li\u003e\n\u003cli\u003eHigh upside if adoption rises\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAbbott’s Early Growth Bets: Big Markets, Small Shares\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAbbott Laboratories’ Question Marks are Lingo, Libre Rio, Volt PFA, TriClip, and connected-care tools: each sits in a big market, but share is still early. Abbott reported $11.9 billion of 2025 Medical Devices revenue, yet these bets still need scale, reimbursement, and broader adoption to turn into Stars.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eWhy Question Mark\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLingo\u003c\/td\u003e\n\u003ctd\u003eEarly DTC biosensor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLibre Rio\u003c\/td\u003e\n\u003ctd\u003eType 2 growth, early share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVolt PFA\u003c\/td\u003e\n\u003ctd\u003eFast market, still scaling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191735623945,"sku":"abt-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/abt-bcg-matrix.webp?v=1783678414","url":"https:\/\/dcfanalyst.com\/products\/abt-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}